Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck

Journal of Clinical Oncology

Volumn 23, Issue 24, 2005, Pages 5578-5587

  Herbst, Roy S ^a   Arquette, Matthew ^a   Shin, Dong M ^a   Dicke, Karel ^a   Vokes, Everett E ^a   Azarnia, Nozar ^a   Hong, Waun Ki ^a   Kies, Merrill S ^a  

^a EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; PACLITAXEL; PLATINUM COMPLEX; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACNE; ANAPHYLACTIC SHOCK; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; HYPERCREATININEMIA; HYPERSENSITIVITY REACTION; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALAISE; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAIL DISEASE; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; ADULT; AGED; DISEASE COURSE; DRUG ADMINISTRATION; HEAD AND NECK TUMOR; MIDDLE AGED; PATHOLOGY; STATISTICAL MODEL; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 24944490558     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.07.120     Document Type: Article

References (36)

1. Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61:203-212, 1990
2. Thompson DM, Gill GN: The EGF receptor: Structure, regulation and potential role in malignancy. Cancer Surv 4:767-788, 1985
3. Schlessinger J: The epidermal growth factor receptor as a multifunctional allosteric protein. Biochemistry 27:3119-3123, 1988
4. Yarden Y, Sliwkowski M: Untangling the ErbB signalling network. Nat Rev Mol Cell Bio 2:127-137, 2001
5. Olayioye M, Neve R, Lane H, et al: The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J 19:3159-3167, 2000
6. Schlessinger J: Cell signaling by receptor tyrosine kinases. Cell 103:211-225, 2000
7. Mendelsohn J, Baselga J: The EGF receptor family as targets for cancer therapy. Oncogene 19:6550-6565, 2000
8. Santini J, Formento JL, Francoual M, et al: Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 13:132-139, 1991
9. Salomon DS, Brandt R, Ciardiello F, et al: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232, 1995
10. Grandis JR, Melhem MF, Gooding WE, et al: Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832, 1998
11. Ang KK, Berkey BA, Tu X, et al: Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356, 2002
12. Kawamoto T, Sato JD, Le A, et al: Growth stimulation of A431 cells by epidermal growth factor: Identification of high-affinity receptors for epidermal growth factor by an anti-receptor monoclonal antibody. Proc Natl Acad Sci USA 80:1337-1341, 1983
13. Mendelsohn J: Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 20:1S-13S, 2002 (suppl 2)
14. Sato JD, Kawamoto T, Le AD, et al: Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors. Mol Biol Med 1:511-529, 1983
15. Masui H, Kawamoto T, Sato JD, et al: Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 44:1002-1007, 1984
16. Goldstein NI, Prewett M, Zuklys K, et al: Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1:1311-1318, 1995
17. Fan Z, Baselga J, Masui H, et al: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637-4642, 1993
18. Baselga J, Norton L, Masui H, et al: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333, 1993
19. Huang SM, Bock JM, Harari PM: Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59:1935-1940, 1999
20. Jemal A, Murray T, Samuels A, et al: Cancer statistics, 2003. CA Cancer J Clin 53:5-26, 2003
21. Forastiere A, Koch W, Trotti A, et al: Head and neck cancer. N Engl J Med 345:1890-1900, 2001
22. Forastiere AA, Metch B, Schuller DE, et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10:1245-1251, 1992
23. Lu C, Kies M: Systemic therapy for recurrent and metastatic diseases, in Harrison LR, Sessions RB, Hong WK (eds): Head and Neck Cancer (ed 2). Philadelphia, PA, Lippincott Williams & Wilkins, 2003, pp 919-925
24. Shin DM, Donato NJ, Perez-Soler R, et al: Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 7:1204-1213, 2001
25. WHO: World Health Organization Handbook for Reporting Results for Cancer Treatment. Geneva, Switzerland, WHO, 1979
26. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
27. List MA, D'Antonio LL, Cella DF, et al: The Performance Status Scale for Head and Neck Cancer Patients and the Functional Assessment of Cancer Therapy-Head and Neck Scale: A study of utility and validity. Cancer 77:2294-2301, 1996
28. Gehan EA: The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346-353, 1961
29. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
30. Baselga J, Trigo J, Bourhis J, et al: Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc Am Soc Clin Oncol 21:226a, 2002 (abstr 900)
31. Trigo J, Hitt P, Koralewski E, et al: Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SSCH): Results of a phase II study. J Clin Oncol 22:488s, 2004 (suppl; abstr 5502)
32. Burtness B, Li Y, Flood W, et al: Phase III trial comparing cisplatin (C) + placebo (P) to C + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC). Proc Am Soc Clin Oncol 21:226a, 2002 (abstr 901)
33. Bonner JA, Harari PM, Giralt J, et al: Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: A phase III study of high dose radiation therapy with or without cetuximab. J Clin Oncol 22:489a, 2004 (suppl; abstr 5507)
34. Cohen E, Rosen F, Stadler W, et al: Phase II trial of ZD 1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003
35. Saltz L, Kies M, Abbruzzese J, et al: The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 22:204a, 2003 (abstr 817)
36. Soulieres D, Senzer NN, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85, 2004